With $115 million, biotech startup Axonis Therapeutics pivots to burgeoning pain field

Axonis Therapeutics, a biotech company that has been quietly operating for the last five years, has raised $115 million after retooling its drug pipeline. 

The startup announced Wednesday that it closed a Series A round led by Cormorant Asset Management and venBio Partners — its first major financing after subsisting on a string of seed financing deals. Sofinnova Investments, MRL Ventures Fund, Perceptive Advisors, and others also participated in the financing round.

Axonis will use the funds to jump into an emerging area of drug development: non-addictive therapies for pain. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In